Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $140,994.86 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Hollman Meyer also recently made the following trade(s):

• On Thursday, January 2nd, Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded up $3.34 during midday trading on Wednesday, hitting $44.65. 998,105 shares of the stock were exchanged, compared to its average volume of 1,131,452. Janux Therapeutics, Inc. has a 1 year low of $7.81 and a 1 year high of $71.71. The company has a 50 day moving average price of $51.33 and a two-hundred day moving average price of $48.42. The firm has a market cap of $2.34 billion, a P/E ratio of -38.16 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics’s quarterly revenue was down 82.6% on a year-over-year basis. As a group, analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Institutional Trading of Janux Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Plato Investment Management Ltd raised its stake in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares during the period. Avanza Fonder AB acquired a new position in Janux Therapeutics during the 4th quarter valued at about $139,000. AQR Capital Management LLC bought a new position in Janux Therapeutics in the 2nd quarter worth about $215,000. Finally, Chicago Capital LLC bought a new stake in Janux Therapeutics during the 4th quarter valued at $230,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JANX. UBS Group began coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective for the company. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price objective on shares of Janux Therapeutics in a report on Wednesday, December 11th. Finally, BTIG Research upped their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Janux Therapeutics has a consensus rating of “Buy” and a consensus target price of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.